Neuphoria Therapeutics Inc share price logo

Neuphoria Therapeutics Inc Share Price

NASDAQ: NEUP

Small Cap

$4.84

-0.19

(-3.78%)

Live

as on

Neuphoria Therapeutics Inc Stock Performance

as on April 22, 2026 at 3:06 am IST

  • Day's Low

    Day's High

    $4.80
    $5.11
    downward going graph

    0.83%

    Downside

    5.58%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.65
    $21.40
    downward going graph

    24.69%

    Downside

    342.16%

    Upside

    downward going graph

Neuphoria Therapeutics Inc share price movements today

Previous Close
$5.03
Open
$5.05
Volume
65.6K
Day's Low - High
$4.80 - $5.11
52 Week Low - High
$3.65 - $21.40

Neuphoria Therapeutics Inc Historical Returns

1 Month Return
+ 9.11 %
3 Month Return
+ 24.5 %
1 Year Return
-3.27 %
3 Year Return
0 %
5 Year Return
0 %

Neuphoria Therapeutics Inc Stock Fundamentals & Key Indicators

Check Neuphoria Therapeutics Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$25.7M

EPS (TTM)

-4.07

Dividend Yield

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

Return On Equity TTM

-26.07%

Neuphoria Therapeutics Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Neuphoria Therapeutics Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Neuphoria Therapeutics Inc image
Neuphoria Therapeutics Inc
NA$25.7MNANA-37.79%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$41.3B126.09%133.478.45%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$111.7B99.85%28.6532.94%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$36.5BNA128.255.37%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$79.2B47.96%18.0531.41%

Stock Returns calculator for Neuphoria Therapeutics Inc Stock including INR - Dollar returns

The Neuphoria Therapeutics Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

Neuphoria Therapeutics Inc investment value today

Current value as on today

₹1,02,174

Returns

₹2,174

(+2.17%)

Returns from Neuphoria Therapeutics Inc Stock

-₹6,923 (-6.92%)

Dollar Impact

₹9,097 (+9.1%)

Neuphoria Therapeutics Inc Stock’s Investor Sentiment and Interest

Search interest for Neuphoria Therapeutics Inc Stock has increased by 22% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:22% versus previous 30 day period

Neuphoria Therapeutics Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
-
-
-
-
-
1
23
-15
-
-
Gross Profit
0
-
0
0
0
0
23
-15
0
0
Operating Income
-5
-6
-3
-8
-5
-5
19
-1,133
-8
-2
EBITDA
-1
-6
-3
-3
-1
-3
18
-846
-14
-2
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
0
0
-
0
0
Income Before Tax
-1
-6
-4
-4
-1
-3
17
-846
-15
1
Income Tax Expense
0
0
0
0
0
0
0
-468
0
0
Net Income
-1
-6
-4
-4
-1
-3
17
-378
-14
1
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
-293.24%
75.08%
2414.30%
0.00%
0.00%

Neuphoria Therapeutics Inc Annual Profit & Loss

All numbers in Millions USD

Jun 2016
Jun 2017
Jun 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Jun 2023
Jun 2024
Jun 2025
Total Revenue
7
18
3
0
0
0
0
-
-
23
Gross Profit
-5
2
-13
-4
-2
-1
0
0
0
22
Operating Income
-28
-13
-30
-20
-11
-12
-28
-22
-26
-1
EBITDA
-22
-9
-30
-13
-4
-6
-28
-21
-22
0
Interest Expense
1
1
1
1
1
1
0
0
-
-
Depreciation
-
-
-
-
-
1
0
0
0
-
Income Before Tax
-26
-12
-34
-17
-8
-9
-29
-22
-23
-1
Income Tax Expense
-9
-6
-8
-6
-3
-1
-6
0
0
0
Net Income
-16
-6
-26
-10
-6
-6
-22
-14
-23
0
Net Profit Margin
-207.75%
-36.58%
-668.33%
-1477.09%
-15255.78%
-931.70%
-8253.62%
0.00%
0.00%
-2.36%

Neuphoria Therapeutics Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-4
-2
-2
0
-1
11
-378
-9
1
Operating Cash Flow
-3
-3
-3
-4
-3
11
73
-3
-6
Investing Cash Flow
-
-
-
-
-
-
-
-
-
Financing Cash Flow
5
1
7
0
0
1
1,527
3
14
Change in Cash
2
-1
4
-4
-3
12
14,271
-3
8

Neuphoria Therapeutics Inc Annual Cash Flow

All numbers in Millions USD

Jun 2017
Jun 2018
Jun 2019
Jun 2020
Jun 2021
Jun 2022
Jun 2023
Jun 2024
Jun 2025
Net Income
-
-
-
-4
-6
-14
-14
-15
-369
Operating Cash Flow
-1
-15
-10
-2
-5
-14
-9
-14
77
Investing Cash Flow
0
0
0
0
0
0
0
-
-
Financing Cash Flow
-1
1
3
-3
23
18
2
15
1,528
Change in Cash
-2
-13
-7
-6
17
3
-15
0
1,601

Insights on Neuphoria Therapeutics Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 months, NEUP stock has moved up by 24.5%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Beone Medicines Ltd has given 38.8% return, outperforming this stock by 42.1%

About Neuphoria Therapeutics Inc

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105 for the treatment of cancer. In addition, it develops NextGen, which is in preclinical trial for the treatment of multiple central nervous system indications; and Kv3.1/3.2 agonist, which is in preclinical trial to treat potential cognitive deficits and negative symptoms/social withdrawal in schizophrenia and autism spectrum disorders. The company has a collaboration with Merck & Co., Inc. to develop a7 receptor positive allosteric modulators targeting cognitive dysfunction associated with alzheimer's disease and other central nervous system conditions. The company was formerly known as Bionomics Limited and changed its name Neuphoria Therapeutics Inc. in December 2024. Neuphoria Therapeutics Inc. was incorporated in 1996 and is based in Burlington, Massachusetts.
OrganisationNeuphoria Therapeutics Inc
Headquarters100 Summit Drive, Burlington, MA, United States, 01803
IndustryBiotechnology
CEODr. Spyridon Papapetropoulos M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Neuphoria Therapeutics Inc

Name

Title

Dr. Spyridon Papapetropoulos M.D., Ph.D.

Interim CEO & Executive Director

Mr. Timothy M. Cunningham CPA, M.B.A.

Chief Financial Officer

Ms. Elizabeth Doolin M.Sc.

Senior Vice President of Clinical Development

Dr. Julie Kerner Ph.D.

Senior Vice President of Business Operations

Mr. Adrian Hinton BEC, F.C.A.

Financial Controller

Mr. Rajeev Chandra B.Com., C.A., M.B.A.

Company Secretary

FAQs

What is Neuphoria Therapeutics Inc share price today?

Neuphoria Therapeutics Inc share price today is $4.84 as on . Neuphoria Therapeutics Inc share today touched a day high of $5.11 and a low of $4.8.

What is the 52 week high and 52 week low for Neuphoria Therapeutics Inc share?

Neuphoria Therapeutics Inc share touched a 52 week high of $21.4 on and a 52 week low of $3.65 on . Neuphoria Therapeutics Inc stock price today i.e. is trending at $4.84,which is 77.38% down from its 52 week high and 32.78% up from its 52 week low.

What is Neuphoria Therapeutics Inc's market capitalisation today?

Neuphoria Therapeutics Inc market capitalisation is $0.00T as on .

How to invest in Neuphoria Therapeutics Inc Stock (NEUP) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Neuphoria Therapeutics Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Neuphoria Therapeutics Inc Shares that will get you 0.3099 shares as per Neuphoria Therapeutics Inc share price of $4.84 per share as on April 21, 2026 at 9:36 pm IST.

What is the minimum amount required to buy Neuphoria Therapeutics Inc Stock (NEUP) from India?

Indian investors can start investing in Neuphoria Therapeutics Inc (NEUP) shares with as little as ₹93.505 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹935.05 in Neuphoria Therapeutics Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Neuphoria Therapeutics Inc share’s latest price of $4.84 as on April 21, 2026 at 9:36 pm IST, you will get 2.0661 shares of Neuphoria Therapeutics Inc. Learn more about fractional shares .